Indoco Remedies

Regulatory Challenges And Capacity Expansion Will Reshape Future Potential

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

26 Jan 25

Updated

30 Jul 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-18.3%

7D

2.6%

Loading

1Y

-18.3%

7D

2.6%

You can edit this narrative until Jul 30 4:30 PM. Then, changes will post as Updates.

Author's Valuation

₹2600.6% overvalued

AnalystConsensusTarget Fair Value

Shared on 30 Jul 25

Fair value Increased 6.45%

The upward revision in Indoco Remedies’ price target is primarily driven by significantly improved forecasts for revenue growth and a higher expected future P/E, resulting in the consensus price target increasing from ₹244.25 to ₹260.00. What's in the News Indoco Remedies will hold a board meeting to consider and approve unaudited financial results for the quarter ended June 2025.

Shared on 21 Jul 25

Fair value Decreased 15%

Despite an improved revenue growth outlook, Indoco Remedies’ consensus price target has dropped notably as a declining future P/E signals reduced market confidence in the company's earnings quality, lowering fair value from ₹286.91 to ₹244.25. What's in the News Indoco's UK subsidiary launched Ticagrelor film-coated tablets 90mg in the UK, to be marketed and distributed by Clarity Pharma.

Shared on 01 May 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 23 Apr 25

Fair value Decreased 1.09%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 8.24%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

Fair value Increased 21%

AnalystConsensusTarget has decreased future PE multiple from 13.8x to 11.4x.